Drug Profile
YKP 10461
Alternative Names: SKL PD; YKP10461Latest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator SK biopharmaceuticals
- Class Antiparkinsonians
- Mechanism of Action Monoamine oxidase B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 28 May 2021 No recent reports of development identified for phase-I development in Parkinson's-disease in USA (PO)
- 22 May 2019 YKP 10461 is still in phase I trial for Parkinson’s Disease in USA (SK Biopharmaceuticals pipeline, May 2019)
- 28 Jan 2019 No recent reports of development identified for phase-I development in Parkinson's-disease in USA (PO)